Lilly’s Forteo Not A “Rational Choice” For Most Osteoporosis, Analysis Finds
Lilly's osteoporosis treatment Forteo (teriparatide) would be cost-effective if the product were 60% cheaper and used sequentially with Merck's Fosamax (alendronate), according to a study published in the Archives of Internal Medicine
You may also be interested in...
An Agency for Healthcare Research & Quality draft report on osteoporosis treatments found that bisphosphonates are not demonstrably superior to less costly treatments
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials